Kodiak Sciences, Inc.
(NASDAQ : KOD)

( )
KOD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.73%296.001.4%$599.53m
AMGNAmgen, Inc.
0.85%235.991.3%$497.59m
GILDGilead Sciences, Inc.
0.00%67.631.0%$369.81m
REGNRegeneron Pharmaceuticals, Inc.
0.76%375.002.6%$304.37m
VRTXVertex Pharmaceuticals, Inc.
-0.25%220.001.9%$274.45m
CLVSClovis Oncology, Inc.
-1.42%13.2414.7%$238.42m
ILMNIllumina, Inc.
0.44%321.993.5%$235.54m
ARWRArrowhead Pharmaceuticals, Inc.
-0.21%67.1811.4%$205.15m
ALXNAlexion Pharmaceuticals, Inc.
0.59%113.132.0%$203.97m
AAgilent Technologies, Inc.
0.17%85.001.6%$165.78m
EXASEXACT Sciences Corp.
0.29%85.4224.0%$161.05m
SRPTSarepta Therapeutics, Inc.
31.38%132.0014.6%$153.57m
BLUEbluebird bio, Inc.
2.92%86.5014.2%$140.73m
GBTGlobal Blood Therapeutics, Inc.
-1.99%76.896.0%$140.66m
BOLDAudentes Therapeutics, Inc.
-0.12%59.371.4%$134.85m

Company Profile

Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.